Akebia Chief Commercial Officer Nicholas Grund resigns effective Nov 6; stays on as consultant

Akebia Therapeutics, Inc.

Nicholas Grund, SVP and Chief Commercial Officer, notified Akebia on Oct 7, 2026 of his resignation for personal reasons; effective Nov 6, 2026.
Grund and the company entered into a Consulting Agreement on Oct 13, 2026, effective as of the Nov 6 resignation date.
Consulting period runs until April 30, 2027, terminable by the company on 10 days' notice or by Grund on 30 days' notice.
Grund will be paid an hourly rate for consulting services during the period; no successor was named in the filing.
Filing signed by President and CEO John P. Butler on October 14, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.